Selina Clifford, General Manager Australia and New Zealand at UCB, said, “Our ambition at UCB is to transform the lives of people living with severe and rare diseases such as myasthenia gravis. We are pleased to bring a new treatment option to healthcare professionals and Australians living with generalised myasthenia gravis.”
Listing delivers access to targeted therapy for Australians living with myasthenia gravis
July 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 22, 2026 - - BioPharma -
Radiopharm Theranostics reports positive results in tumour trials
July 22, 2026 - - Australian Biotech -
Proteomics International and Healius team up to take Promarker tests national
July 22, 2026 - - Australian Biotech

